Observe Medical ASA Revenue and Competitors
Estimated Revenue & Valuation
- Observe Medical ASA's estimated annual revenue is currently $2.5M per year.
- Observe Medical ASA's estimated revenue per employee is $98,000
Employee Data
- Observe Medical ASA has 26 Employees.
- Observe Medical ASA grew their employee count by 8% last year.
Observe Medical ASA's People
Name | Title | Email/Phone |
---|
Observe Medical ASA Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $2.2M | 22 | 5% | N/A | N/A |
#2 | $25.7M | 167 | -52% | N/A | N/A |
#3 | $7.7M | 61 | 7% | N/A | N/A |
#4 | $7.4M | 59 | -6% | N/A | N/A |
#5 | $22M | 143 | N/A | N/A | N/A |
#6 | $3.4M | 30 | 0% | N/A | N/A |
#7 | $14.4M | 103 | 6% | N/A | N/A |
#8 | $41.7M | 271 | -13% | N/A | N/A |
#9 | $2.5M | 26 | 8% | N/A | N/A |
#10 | $4.7M | 42 | 2% | N/A | N/A |
What Is Observe Medical ASA?
Observe Medical is a medtech company, listed on the Oslo Axess stock exchange, and with main operations in Sweden. Core product is Sippi®, the only digital urine measurement system for use in hospital intensive care units, with wireless data transfer to patient data management system and which also prevents bacterial migration which can lead to urinary infections.
keywords:N/AN/A
Total Funding
26
Number of Employees
$2.5M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Observe Medical ASA News
2022-04-20 - Effect of Systemic Lidocaine on Postoperative Early Recovery | DDDT
After surgery, patients were transferred to postanesthesia care unit (PACU) for further observation. When extubation indications were met, the...
2022-04-13 - Women were less likely to return to work after a severe stroke, new ...
To recognize stroke symptoms requiring immediate medical attention, ... For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.7M | 26 | -16% | N/A |
#2 | N/A | 26 | 37% | N/A |
#3 | N/A | 26 | 53% | N/A |
#4 | N/A | 26 | 86% | N/A |
#5 | $2.9M | 26 | 44% | N/A |